UC Riverside Tests Novel Protein Therapy for Fragile X Syndrome

At UC Riverside's School of Medicine, a laboratory is preparing to test whether engineered proteins can repair the broken machinery inside the brains of mice with Fragile X syndrome. The work, funded by a $100,000 grant from the FRAXA Research Foundation, represents a convergence of two fields that rarely intersect: academic neuroscience and biotechnology innovation. For the first time, researchers have access to proteins designed to cross one of the body's most formidable barriers—the blood-brain barrier—and deliver therapeutic function directly where it's needed.

Fragile X syndrome affects roughly 100,000 Americans. The condition stems from mutations in the FMR1 gene, which disrupts production of a critical protein called FMRP. Without it, the brain develops abnormally. People with Fragile X experience intellectual disability, struggle with learning and memory, face social and behavioral challenges, and often react intensely to sensory input. The disorder is also a significant genetic cause of autism spectrum disorder. For decades, the condition has resisted treatment because the proteins needed to correct it couldn't reliably reach brain tissue.

Dr. Devin Binder, a biomedical sciences professor, has spent years measuring the abnormal electrical activity that occurs in Fragile X brains. His laboratory uses electroencephalography—EEG recordings—to capture brain activity in living animals as they move and respond to stimuli. The Fragile X knockout mouse, a standard research model, exhibits the same kinds of brain abnormalities seen in affected humans: disrupted sensory processing and chaotic neural coordination. Binder's team has already documented specific EEG patterns that distinguish Fragile X mice from normal ones. Those measurements will serve as the baseline for the new experiment.

The proteins being tested come from Bowen's FX Therapeutics, a biotechnology company that has engineered versions of the missing Fragile X protein to solve a problem that has long stalled neurological drug development. Most therapeutic molecules cannot cross the blood-brain barrier—a selective filter that protects the brain but also locks out most medicines. Bowen's team used protein engineering to create versions that can be administered systemically, entering the bloodstream and penetrating into brain tissue where they can restore function.

Over the next year, Binder's laboratory, led in part by research associate Carrie Jonak, will administer these engineered proteins to Fragile X mice and measure what happens to their brain activity. The measure of success is straightforward: if the treated mice's brain physiology begins to resemble that of normal mice, if the abnormal EEG patterns normalize, the experiment will have worked. Binder is careful to note that this pilot study won't directly test whether the mice learn or remember better. But if brain physiology corrects itself, he reasons, cognitive and behavioral improvements should follow.

For Binder, the moment feels historic. When he entered neuroscience, the idea of engineering a protein that could cross the blood-brain barrier and restore function seemed like science fiction. Now it's happening in his lab, made possible by a partnership between academic expertise in measuring brain function and a private company's breakthrough in protein delivery. The collaboration exists because foundation funding created the bridge. Without it, Binder said, his laboratory would never have had access to this kind of therapeutic technology. If the mice respond as hoped, the path toward human trials becomes clearer—and 100,000 Americans living with Fragile X syndrome move one step closer to a treatment that might change their lives.